Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Tirzepatide
Drug: Insulin Degludec

First Posted Date: 2019-03-20

Last Posted Date: 2022-01-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1444

Registration Number: NCT03882970

Locations: 🇺🇸
Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸
National Research Institute, Panorama City, California, United States
🇺🇸
Catalina Research Institute, LLC, Montclair, California, United States

and more 115 locations

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Tirzepatide
Drug: Dulaglutide

First Posted Date: 2019-03-04

Last Posted Date: 2022-04-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 636

Registration Number: NCT03861052

Locations: 🇯🇵
Medical Corporation Chiseikai Tokyo Center Clinic, Chuo-ku, Tokyo, Japan
🇯🇵
Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan
🇯🇵
IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan

and more 43 locations

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Tirzepatide
Drug: Oral antihyperglycemic medication (OAM)

First Posted Date: 2019-03-04

Last Posted Date: 2022-02-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 443

Registration Number: NCT03861039

Locations: 🇯🇵
Yuri Ono Clinic, Sapporo, Hokkaido, Japan
🇯🇵
Miyanomori Hospital, Sapporo, Hokkaido, Japan
🇯🇵
Ikeda Hospital, Amagasaki, Hyogo, Japan

and more 31 locations

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Device: AID System
Drug: Insulin Lispro

First Posted Date: 2019-02-21

Last Posted Date: 2019-04-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10

Registration Number: NCT03849612

Locations: 🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Device: AID System
Drug: Insulin Lispro

First Posted Date: 2019-02-21

Last Posted Date: 2019-04-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10

Registration Number: NCT03848767

Locations: 🇺🇸
Rainier Clinical Research Center, Renton, Washington, United States

Study of Ixekizumab in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Biological: Ixekizumab

First Posted Date: 2019-02-20

Last Posted Date: 2022-11-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT03848403

Locations: 🇺🇸
Covance, Dallas, Texas, United States
🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States

A Study of Ixekizumab in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Ixekizumab

First Posted Date: 2019-02-20

Last Posted Date: 2020-06-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 99

Registration Number: NCT03848416

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3437943

First Posted Date: 2019-02-15

Last Posted Date: 2019-08-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 45

Registration Number: NCT03841630

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

Phase 3

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Baricitinib
Drug: Placebo

First Posted Date: 2019-02-15

Last Posted Date: 2023-05-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1147

Registration Number: NCT03843125

Locations: 🇺🇸
New England Research Associates, Bridgeport, Connecticut, United States
🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸
Integral Rheumatology & Immunology Specialists, Plantation, Florida, United States

and more 293 locations

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Ultra-Rapid Lispro
Drug: Insulin Lispro

First Posted Date: 2019-02-05

Last Posted Date: 2021-01-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 471

Registration Number: NCT03830281

Locations: 🇺🇸
Marin Endocrine Associates, Greenbrae, California, United States
🇺🇸
Diabetes and Endocrine Associates, La Mesa, California, United States
🇺🇸
Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States

and more 76 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy